The disruption of immune system is a key candidate in the pathogenesis of psychiatric disorders, especially those resistant to traditional treatments. Involving complex processes within the brain and peripheral immune system, inflammation may lead to imbalance of neurotransmitter systems and synaptic plasticity and directly contribute to the psychiatric symptoms observed in conditions such as depression, bipolar disorder (BD) and schizophrenia (SCZ).
Studies show that treatment-resistant depression (TRD) is associated with elevated levels of inflammatory markers in the blood, which are linked to a lower response to conventional antidepressants. Interventions that modulate this inflammatory response, such as immunomodulatory treatments or therapies targeting pro-inflammatory cytokines, have demonstrated beneficial effects by reducing symptoms and improving patients' quality of life.
A thorough understanding of the links between inflammation and treatment resistance therefore paves the way for innovative therapeutic strategies. These approaches could transform current practices by offering more personalized and effective solutions for patients suffering from chronic and resistant psychiatric disorders.
Patient aged ≥ 18 years old;
Patient suffering from a psychiatric disorder according to DSM-5 criteria;
Patient with drug-resistant disease according to the definition of the protocol
Patient starting a new treatment for his pathology;
Patient with major neurocognitive disorder diagnosed (dementia syndrome)
Pregnant, laboring, or breastfeeding female patients
Patient deprived of liberty by judicial or administrative decision. Patient in psychiatric care under constraints may be included.
For patients accepting the lumbar punction: patients who are unable to control themselves and are likely to engage in physical or violent behavior.
Centre Hospitalier St Anne
Lead sponsor
GHU Paris Psychiatry & Neurosciences
Collaborator